Durvalumab vs Osimertinib

## Durvalumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Osimertinib**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Osimertinib**: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Osimertinib — 48 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Osimertinib — C28H33N7O2.

**Molecular Weight**: Durvalumab — N/A; Osimertinib — 499.6050 g/mol.

**Type**: Durvalumab — Antibody; Osimertinib — Small molecule.